KLK3 and pachyonychia congenita: Despite the good overall control of the disease progression after RP, 20–30% of patients experience PC recurrence that manifests in an increase in the prostate-specific antigen (PSA) in the serum without any clinical evidence of metastatic disease (MD) [12].